Anti-inflammatories for depression: challenges and ASPIRations
- PMID: 41115445
- DOI: 10.1016/S2215-0366(25)00308-6
Anti-inflammatories for depression: challenges and ASPIRations
Conflict of interest statement
The following authors report consultancy or speaker fees: LDP (Boehringer Ingelheim Belgium); SMG (Hexal, Tegus, Angelini, and Streamed up); FL (Noema Pharma, Novo Nordisk, and Johnson & Johnson); JCF (Ventus Therapeutics); BVJHP (Neurotorium and Boehringer Ingelheim); BTB (AstraZeneca, Lundbeck, Pfizer, Takeda, Servier, Bristol Myers Squibb, Otsuka, LivaNova, Biogen, Angelini, and Janssen–Cilag); AHM (Cerevel Therapeutics, Freedom Biosciences, and Sirtsei Pharmaceuticals); DJS (Discovery Vitality, Johnson & Johnson, Kanna, L’Oréal Lundbeck, Orion, Sanofi, Servier, Takeda, and Vistagen); and CMP (Värde Partners, Compass Pathways, and UCB). All other authors declare no competing interests. This work was supported by the Wellcome Trust Advanced Stratification of People with Depression (ASPIRE) Study (30312/Z/23/Z).
LinkOut - more resources
Full Text Sources
